Hot Pursuit     22-Jun-24
Cipla Goa facility gets 6 USFDA observations
The drug major said that the US drug regulator has issued Form 483, with six observations after inspecting its Goa manufacturing facility.

The United States Food and Drug Administration (USFDA) had conducted an inspection at the company's Goa manufacturing facility from 10 June 2024 to 21 June 2024.

In a regulatory filing, Cipla said, “On conclusion of the inspection, the company received ix inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.”

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The pharma company reported 79% jump in consolidated net profit to Rs 939.04 crore on 10% increase in revenue from operations to Rs 6,163 core in Q4 FY24 over Q4 FY23.

Shares of Cipla fell 0.60% to end at Rs 1,535.15 on Friday, 22 June 2024.

Previous News
  USFDA classifies inspection of Cipla's Kurkumbh unit as Voluntary Action Indicated
 ( Corporate News - 13-Jul-24   12:02 )
  Cipla allots 35,106 equity shares under ESOP
 ( Corporate News - 05-Jul-24   11:02 )
  Cipla to conduct board meeting
 ( Corporate News - 05-Jul-24   10:23 )
  Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
 ( Corporate News - 28-Jun-24   19:23 )
  Cipla Ltd eases for fifth straight session
 ( Hot Pursuit - 25-Jun-24   13:35 )
  USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'
 ( Corporate News - 25-Jun-24   12:12 )
  Cipla gets VAI classification from USFDA for Patalganga facility
 ( Hot Pursuit - 25-Jun-24   11:34 )
  Cipla slides as Goa facility gets 6 USFDA observations
 ( Hot Pursuit - 24-Jun-24   09:47 )
  Cipla Goa facility gets 6 USFDA observations
 ( Hot Pursuit - 22-Jun-24   16:22 )
  Cipla's Goa unit completes USFDA inspection
 ( Corporate News - 22-Jun-24   11:47 )
  Cipla to invest additional EUR 3 million in Ethris GmbH
 ( Corporate News - 18-Jun-24   17:19 )
Other Stories
  Lupin receives EIR from USFDA for Dabhasa facility
  13-Jul-24   16:48
  RVNL secures LoA worth Rs 132 cr from Central Railway
  13-Jul-24   16:38
  EMS bags order worth Rs 141-cr from Uttarakhand Power Corp.
  13-Jul-24   16:14
  Avenue Supermarts Q1 PAT climbs 17% YoY to Rs 774 cr in FY25
  13-Jul-24   16:00
  Sunteck Realty pre-sales climbs 30% YoY to Rs 502 cr in FY25
  13-Jul-24   15:32
  Fitch Ratings revises outlook on ratings of Tata Steel to 'negative'
  13-Jul-24   14:46
  5Paisa Capital Q1 PAT jumps 38% YoY in FY25
  13-Jul-24   14:39
  HCL Tech records PAT of Rs 4,257 crore in Q1; EBIT margin at 17.1%
  13-Jul-24   11:59
  IREDA Q1 PAT rises 30% YoY to Rs 384 cr in FY25
  13-Jul-24   09:00
  GTPL Hathway slides after Q1 PAT drops 60% YoY to Rs 14 cr in FY25
  12-Jul-24   15:40
Back Top